UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
BIOTECHNOLOGY

Regeneron Pharmaceuticals

R

Regeneron Pharmaceuticals

BiotechnologyTarrytown, United States
Visit Website

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals built one of the most productive drug-discovery engines in the industry, turning its proprietary VelociSuite technology platform into a stream of approved medicines across immunology, oncology, ophthalmology, and rare disease.

VelociSuite: The Engine Behind the Pipeline

Founded in 1988 and headquartered in Tarrytown, New York, Regeneron developed VelociSuite as a set of integrated technologies for generating fully human antibodies at speed and scale. VelocImmune, the flagship component, replaced mouse immune systems with human equivalents, dramatically improving the translatability of antibody candidates from preclinical work into clinical development. This approach underpins the majority of Regeneron's approved portfolio and its extensive collaboration pipeline.

Approved Portfolio and Collaboration Network

The company's commercial portfolio includes treatments for atopic dermatitis, asthma, chronic sinusitis with nasal polyps, high cholesterol, wet age-related macular degeneration, diabetic eye disease, cervical cancer, and rare blood disorders, among other indications. Dupixent, co-developed and co-commercialised with Sanofi, became one of the best-selling medicines globally and continues to be studied across a broad range of type 2 inflammatory conditions. Eylea, targeting vascular endothelial growth factor, remains a leading treatment in retinal disease.

Regeneron's long-standing alliance with Sanofi covers immunology and oncology, while the company maintains an oncology collaboration with Bayer centred on cancer therapy. The company also operates Regeneron Genetics Center, one of the largest human genetics programmes in the world, partnering with health systems to sequence patient genomes and identify novel drug targets. Listed on Nasdaq under the ticker REGN, Regeneron employs tens of thousands of people globally, with significant research and manufacturing infrastructure concentrated in New York State.

Further information is available at regeneron.com.

Similar Companies

More in Biotechnology

A

Adagene

A proprietary antibody engineering platform sits at the core of Adagene, a Nasdaq-listed, clinical-stage immunotherapy company working to redefine how antibodies are discovered and designed for cancer treatment. Operating globally, the company has built its approach around the Dynamic Precision Library, a computational and structural biology platform that generates antibody candidates with enhanced precision and therapeutic potential. Three distinct antibody modalities underpin the platform. NEObody candidates are designed to access previously undruggable epitopes; SAFEbody molecules incorporate a masking mechanism intended to improve the therapeutic window; and POWERbody formats are engineered for potentiated immune engagement. Together, these technologies give Adagene a differentiated toolkit for addressing difficult oncology targets. The company's clinical pipeline includes ADG126, ADG116, ADG206 and ADG106, each progressing through clinical evaluation as part of a broader portfolio that also encompasses preclinical programmes. Adagene pursues its development objectives both independently and through external collaborations, reflecting a partnered model that extends the reach of its platform across the industry. As a public company listed on Nasdaq, Adagene operates under the governance and disclosure standards associated with that market, with oversight from a board of directors and a scientific and strategic advisory board. The organisation's commitment to antibody innovation positions it within the competitive immuno-oncology space, where platform differentiation and clinical progress are the key measures of progress. Further information is available at adagene.com.

View profile
R

Recursion Pharmaceuticals

Recursion Pharmaceuticals built its identity around a simple but radical premise: that biology can be treated as a data problem. Founded in 2013 and headquartered in Salt Lake City, Utah, the company combines high-throughput cellular imaging, machine learning, and automation to map the effects of compounds across millions of biological experiments per week, generating one of the largest proprietary datasets in drug discovery. The company went public on Nasdaq in 2021, trading under the ticker RXRX, and has since expanded its platform infrastructure significantly. Its Recursion OS integrates wet-lab robotics with computational models, enabling the company to generate and interpret biological data at a scale not feasible through conventional methods. This positions Recursion less as a traditional drug developer and more as a technology-driven drug discovery platform, with partnerships and licensing arrangements alongside its own pipeline. Recursion's therapeutic focus spans oncology, rare genetic diseases, and infectious disease, with programmes emerging directly from its machine-learning-guided discovery process rather than target-by-target hypothesis generation. The company has established significant collaborations with large pharmaceutical organisations, using its platform to explore indications and compound interactions that would be difficult to surface through legacy approaches. With operations extending beyond Utah and a growing team of scientists, engineers, and data specialists, Recursion represents a distinct category within the life sciences: a company where computational infrastructure is as central to the enterprise as laboratory science. Its model has attracted attention from investors and partners seeking industrialised, reproducible approaches to early-stage drug discovery. Further information is available at recursion.com.

View profile
A

Alchemab Therapeutics

A proprietary platform for mining human antibody repertoires sits at the core of Alchemab Therapeutics, a clinical-stage biotechnology company working to identify novel drug targets and therapeutics by reverse engineering the biology of resilient patients. Rather than starting from disease biology alone, the approach begins with well-defined patient samples drawn from individuals who are susceptible to a condition yet remain protected from it, using deep B cell sequencing and computational analysis to identify convergent protective antibody responses across that population. The platform is designed to surface drug candidates that conventional discovery programmes are unlikely to find, making it particularly well suited to hard-to-treat diseases where existing therapeutic options remain limited. Alchemab has built its initial pipeline around neurodegenerative conditions and oncology, two areas where unmet medical need remains high and mechanistic understanding of protective immunity is still emerging. Access to the highly specialised patient samples that power the platform depends on a network of partnerships with patient representative groups, biobanks, industry partners, and academic institutions. These collaborations are central to the company's discovery model, ensuring that the antibody repertoire data feeding the computational analysis pipeline reflects genuine protective biological signals rather than population averages. Alchemab is led by Chief Executive Officer Jane Osbourn, OBE, FMedSci, PhD, who brings substantial scientific and commercial experience from the biotech and pharmaceutical sector. The broader executive and scientific leadership team is described as combining deep domain expertise with an ambitious development agenda across the company's growing pipeline. Further information is available at alchemab.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy